Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The fixed-dose combination of sofosbuvir, a nucleotide analogue NS5B polymerase inhibitor, and velpatasvir, a second-generation NS5A inhibitor, has been approved by the United States Food and Drug Administration and the European Medicines Agency for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection. This combination, administered over 12 weeks as a single-tablet regimen, has resulted in high cure rates in all 6 HCV genotypes and in a variety of patient populations, including patients without cirrhosis, patients with compensated cirrhosis and patients with HIV coinfection. In patients with decompensated cirrhosis, high cure rates were also achieved over 12 weeks with sofosbuvir/velpatasvir plus ribavirin. Patients who had failed prior treatment with an NS5A-containing regimen were able to achieve high cure rates following 24 weeks of treatment with sofosbuvir/velpatasvir plus ribavirin. Sofosbuvir/velpatasvir was well tolerated, the most common adverse events being headache, fatigue and nausea.

Original languageEnglish (US)
Pages (from-to)177-189
Number of pages13
JournalDrugs of Today
Issue number3
StatePublished - Mar 1 2017


  • Direct-acting antiviral
  • Hepatitis C virus
  • Sofosbuvir
  • Velpatasvir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection'. Together they form a unique fingerprint.

Cite this